Earnings Feed
Start Free
BOSTON SCIENTIFIC CORP·4

Feb 3, 4:12 PM ET

Mahoney Michael F 4

Research Summary

AI-generated summary

Updated

Boston Scientific CEO Michael Mahoney Exercises Options, Sells Shares

What Happened

  • Michael F. Mahoney, Chairman, President & CEO of Boston Scientific (BSX), exercised two stock option grants on Feb 2, 2026 to acquire 95,754 shares (49,407 @ $24.55 and 46,347 @ $27.09) at a total exercise cost of $2,468,482. On the same day he sold 160,901 shares in open‑market transactions (1,200 @ $94.06 and 159,701 @ $93.49) for a combined sale proceeds of about $15,043,394. The filing also lists corresponding derivative disposition entries at $0 for the exercised option lots (reporting related to the exercise/conversion).

Key Details

  • Transaction date: February 2, 2026; Form 4 filed Feb 3, 2026 (next‑day filing).
  • Options exercised: 49,407 shares at $24.55 ($1,212,942) and 46,347 shares at $27.09 ($1,255,540) — total 95,754 shares, $2,468,482 exercise cost.
  • Shares sold: 1,200 @ $94.06 ($112,868) and 159,701 @ $93.49 ($14,930,526) — total 160,901 shares, ~$15,043,394 proceeds.
  • Sales were effected under a pre‑established Rule 10b5‑1 trading plan adopted Aug 29, 2025 (Footnote F1).
  • Footnotes note weighted average sale prices and price ranges: $94.00–$94.13 for the small block (F2) and $93.00–$93.985 for the larger block (F3).
  • The filing shows derivative disposition lines with $0 value for the exercised option lots (common reporting practice for option conversion); no separate tax‑withholding entry is shown in the provided excerpt.
  • Shares owned after the transactions are not disclosed in the supplied excerpt.

Context

  • This was an exercise of vested options followed by open‑market sales; because the sales were done under a pre‑established 10b5‑1 plan, they are typically treated as routine, preplanned transactions rather than opportunistic trades.
  • For retail investors: purchases (buys) often carry a stronger signal than routine sales, but option exercises followed by sales are common for executives to cover exercise costs, taxes, or diversify. This filing is primarily reporting an option exercise plus substantial open‑market sales rather than an unsolicited purchase.